Table 2.

Response rates (overall and in the HR+ group)

Total (n = 37)HR+ (n = 33)
Complete response00
PR2 (5%)2 (6%)
SD < 6 months14 (38%)13(39%)
SD ≥ 6 months5 (14%)5 (16%)
PD16 (43%)13 (39%)
CBR7/377/33
 (PR + ≥6 mo SD)(19%)(21%)
CBR by prior metastatic hormonal therapy
 0 or 1 prior lines hormoneN/A0/9 (0%)
 ≥2 prior lines hormone7/24 (29%)
  Fisher exact test, P0.081
CBR by prior metastatic chemotherapy
 0 or 1 prior lines chemotherapy4/9 (44%)4/9 (44%)
 ≥2 prior lines chemotherapy3/28 (11%)3/24 (13%)
  Fisher exact test, P0.0450.068
Duration of response, months (median, range)4 (2–5)5 (2–6)